In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on GeoVax Labs (GOVX – Research Report), with a price target of $6.00. The company’s shares closed last Friday at $0.56.
LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, GeoVax Labs, and Tonix Pharma. According to TipRanks, LeBoyer has an average return of -7.0% and a 26.88% success rate on recommended stocks.
Currently, the analyst consensus on GeoVax Labs is a Moderate Buy with an average price target of $7.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on GeoVax Labs’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.04 million. In comparison, last year the company had a GAAP net loss of $2.43 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.
Read More on GOVX:
- GeoVax Labs initiates Phase 2 trial of COVID-19 vaccine booster in CLL
- GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
- GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
- GeoVax Labs presents Gedeptin clinical data at the AACR-AHNS
- GeoVax Labs announces Gedeptin presentation at AACR-AHNS conference
